Mereo BioPharma Group plc (ADR)
General ticker "MREO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $387.9M (TTM average)
Mereo BioPharma Group plc (ADR) does not follow the US Stock Market performance with the rate: -9.0%.
Estimated limits based on current volatility of 5.2%: low 1.82$, high 2.02$
Factors to consider:
- Total employees count: 33 as of 2023
- Top business risk factors: Geopolitical risks, Limited operating history, Regulatory and compliance, Cybersecurity threats, Market competition
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.21$, 4.83$]
- 2025-12-31 to 2026-12-31 estimated range: [1.94$, 4.32$]
Short-term MREO quotes
Long-term MREO plot with estimates
Financial data
| YTD | 2024-12-31 |
|---|---|
| Operating Revenue | $0.00MM |
| Operating Expenses | $47.36MM |
| Operating Income | $-47.36MM |
| Non-Operating Income | $4.11MM |
| Interest Expense | $1.37MM |
| R&D Expense | $20.93MM |
| Income(Loss) | $-43.25MM |
| Profit(Loss)* | $-43.25MM |
| Stockholders Equity | $60.97MM |
| Assets | $76.39MM |
| Operating Cash Flow | $-32.83MM |
| Capital expenditure | $0.70MM |
| Investing Cash Flow | $-0.70MM |
| Financing Cash Flow | $46.15MM |
| Earnings Per Share** | $-0.29 |
| Ordinary share to ADR | 0.20x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.